In recent months, Haemonetics has reported a recovery in its Hospital division, supported by broader adoption of its FDA-approved NexSys PCS system with Persona Technology and the completed transition ...

Haemonetics HAE has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently.

Haemonetics describes its machines as the most popular devices used at plasma collection centers, the facilities where donors are paid to give plasma. CSL Plasma, the largest of those plasma ...

HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.

Donating plasma has long been a way of making money, especially among people on the financial margins. Unlike with blood, plasma donors are paid cash and can donate twice a week. Plasma, the liquid ...